Visual function disorder improving agents
AssigneesSenju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation
InventorsYoshiko Takayama, Yukuo Yoshida, Masayoshi Uehata
Life of this patent
Estimating the term…
Abstract
The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.
Claims7
1-40. (canceled)
A method of improving a visual function disorder caused by damage or degeneration of retinal nerve cell or optic nerve, which comprises administering an effective amount of a compound having Rho kinase inhibitory activity to a patient, wherein the compound having Rho kinase inhibitory activity is a compound selected from thiochroman compounds, isoquinolinesulfonamide derivatives, vinylbenzene derivatives and ethacrynic acid, or a pharmaceutically acceptable salt thereof.
42-48. (canceled)
A method of promoting extension of axon of a retinal ganglion cell, which comprises administering an effective amount of a compound having Rho kinase inhibitory activity to a patient, wherein the compound having Rho kinase inhibitory activity is a compound selected from thiochroman compounds, isoguinolinesulfonamide derivatives, vinylbenzene derivatives and ethacrynic acid, or a pharmaceutically acceptable salt thereof.
50-54. (canceled)
A method of promoting regeneration of an optic nerve cell, which comprises administering an effective amount of a compound having Rho kinase inhibitory activity to a patient, wherein the compound having Rho kinase inhibitory activity is a compound selected from thiochroman compounds, isoquinolinesulfonamide derivatives, vinylbenzene derivatives and ethacrynic acid, or a pharmaceutically acceptable salt thereof.
56-81. (canceled)
Dependencies are inferred from the claim text.